FDA in Drafting Phase for LDT Oversight | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – The US Food and Drug Administration is currently drafting its plans for regulating laboratory-developed tests and is considering available options, such as using a risk-based approach for oversight and a registry of tests to know what services are available, an FDA official told the Secretary's Advisory Committee for Genetics, Health, and Society today.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Pacific Biosciences is hosting a competition in which researchers are vying to win free sequencing for an organism with the most interesting genome.

An opinion piece appearing in Newsday likens familial DNA searches to stop-and-frisk policies.

The San people of Africa have drawn up a code of conduct for researchers, according to the Conversation.

In Nature this week: genotypes linked to hip osteoarthritis, and more.